Do You Have Challenges Upscaling Your Chromatography?

Get Tips to Upscaling You Downstream Process (while You Reduce Risk)

Upscaling chromatography is a hot topic at the moment – and many companies fail. At Peak Biotech we've successfully scaled downstream processes for some of the biggest pharmas in the world. At BioProcess International 2026 we would like to meet up with interested parties to share some of our results.

Book a personal meeting below and learn:

How you can scale up your downstream process without losing performance
How you can reduce cost without increasing risk
How you can design your downstream
processes for increasingly complex modalities

Book our Chief Commercial Officer – Malene Linderoth – in the form below and get tips on how you can upscale your downstream process, reduce risk and move from empirical development to predictable design.

100% free with no obligations. Coffee and inspiration on us!

Case:

Your Chromatography Platform Isn't Broken — Your Column Just Can't Keep Up

Platform chromatography was designed for monoclonal antibodies and works well there, but newer modalities like bispecifics and viral vectors push it beyond its original assumptions. The real bottleneck isn't the method — it's whether the column can physically sustain the required flow, pressure, and packing conditions.

As molecule diversity grows, packing uniformity and bed stability become critical to avoiding constant method re-tuning. The future of platform chromatography lies in defining a stable operating space broad enough for multiple modalities, rather than a fixed step-by-step recipe. The column is not a passive container — it is the foundation on which platform applicability actually depends.

Reach out to Get the Full Case Story.